on september 5, the awarding ceremony of the 4th "china translational medicine award" was held in beijing. dr. aimin hui, fosun pharma's executive president, president of global r&d, and chief medical officer, was granted the 4th "china translational medicine award - international collaboration".
the "translational medicine award program" was jointly initiated by shanghai guangci translational medical research foundation and national facility for translational medicine to reward experts and scholars who have made outstanding contributions in the field of translational medicine research, as well as clinicians and scientific researchers who have made breakthrough innovations. a total of 1 winner of "china translational medicine award - international collaboration", 2 winners of "china translational medicine award - outstanding contribution" and 5 winners of "china translational medicine award - innovation" were selected at this awarding ceremony. among them, the "china translational medicine award - international collaboration" aims to reward those who are committed to promoting international cooperation and exchanges in translational medicine and promoting the smooth transformation of medical research achievements worldwide.
"dr. aimin hui, president of fosun pharma global r&d, has comprehensively led the innovation, r&d, update of products for fosun pharma. the clinical programs regarding innovator drugs have increased by 30 times in the past three years, and multiple zero breakthroughs have been achieved in fosun pharma, namely the first clinical trial overseas, the first innovator drug, the first fast track designation granted by u.s. food and drug administration, the first fda orphan drug designation, and the first innovator drug approved for marketing. dr. aimin hui has actively promoted international cooperation and exchanges in such fields as tumors, mrna vaccines, stem cells. as the program director and chief medical officer, he has led the china-germany covid-19 mrna vaccine development program. this mrna vaccine (bnt162b2) has been included in the government vaccination programs in hong kong and macao, china, playing a positive and critical role in local epidemic prevention and control. it is of great significance to the r&d layout of covid-19 vaccines in china." said the review committee at this ceremony.
about fosun pharma
founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. (“fosun pharma”; stock code: 600196.sh, 02196.hk) is a global innovation-driven pharmaceutical and healthcare industry group deeply rooted in china with strategic layouts in the pharmaceutical and healthcare industrial chain. fosun pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm group co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
fosun pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. through independent r&d, cooperative development, license-in, and in-depth incubation, fosun pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy in such major disease areas as tumors, immunological diseases, 4 high health risks (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system diseases. moreover, fosun pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, rna, oncolytic virus and gene therapy to enhance its innovation ability.
looking forward, under the guidance of 4in strategy (innovation, internationalization, integration and intelligentization), fosun pharma strives to be a leading enterprise in the global pharmaceutical and healthcare markets by practicing the development model based on innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development.
for more information, please visit our official website: 凯发k8娱乐app下载-凯发k8娱乐官网入口